Agilent Technologies Inc. (NYSE: A) today announced an extension to its longstanding agreement with PerkinElmer, which supplies chips for Agilent's popular 2100 Bioanalyzer system.

Since its introduction in 1999, the 2100 Bioanalyzer system has become an integral part of molecular biology laboratories around the world. It is used in DNA sequencing, gene expression, DNA fragment analysis, quality control for protein-based drugs, and other applications.

"This agreement ensures that, for years to come, molecular biologists can continue to depend on the sample quality and high-fidelity data they obtain with the Agilent 2100 Bioanalyzer system," said Dr. Knut Wintergerst, marketing and support manager for microfluidics at Agilent.